OTC · Medical - Pharmaceuticals

MabCure Inc. (MBCI) Stock

$0.00 OTC: MBCI Healthcare

MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers.

Valuation

MetricValue
Price$0.00
Market Cap$21965
P/E Ratio0.00
P/B Ratio0.01
P/S Ratio0.02
EPS (TTM)$-0.01
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-125.14%
ROA-4.22%
ROCE-18.31%
Gross Margin100.00%
Operating Margin45.31%
Net Margin-1200.00%
Debt/Equity0.08
Current Ratio0.17

Annual Financials (USD)

Metric20072008200920102011
Revenue$0$0$0$0$1.0M
Operating Profit$0$-1.0M$-1.0M$-1.0M$-1.0M
Net Profit$0$-1.0M$-1.0M$-1.0M$-12.0M
EPS$0.00$-0.01$-0.02$-0.02$-0.20
Op Margin————-141.9%

Balance Sheet (USD)

Metric20072008200920102011
Total Assets$0$19.0M$19.0M$16.0M$5.0M
Total Liabilities$0$0$1.0M$0$1.0M
Cash$0$1.0M$0$0$0
Borrowings$0$0$1.0M$0$0

Cash Flow (USD)

Metric20072008200920102011
Operating Cash Flow$0$0$-1.0M$-1.0M$0
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$0$1.0M$-1.0M$0$0
Free Cash Flow$0$-1.0M$-1.0M$-1.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.01
FCF Yield-285.24%
Quick Ratio0.17
Interest Coverage-3.80
Return 1Y100.00%
Return 3Y-33.33%
Return 5Y—

Ownership

Insiders Held0.00%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BPIGFBPI Energy Holdings, Inc $0.00 — 0.00 $7010 0.00%
GSLOGo Solar USA, Inc. $0.00 — 0.00 $6543 0.00%
ISUNQiSun, Inc. $0.00 — 0.00 $4738 0.00%
OEDVQOsage Exploration and Development, Inc. $0.00 — 0.00 $5828 0.00%
QOILQuest Oil Corporation $0.00 — -448.52 $149806 0.00%

About MabCure Inc.

MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.

MabCure Inc. (MBCI) stock trades at $0.00 with a market capitalization of $21965. The stock is valued at price-to-book of 0.01, price-to-sales of 0.02.

On profitability, MabCure Inc. generates a return on equity (ROE) of -125.14% (negative, reflecting a net loss), return on capital employed of -18.31%, an operating margin of 45.31%, a net profit margin of -1200.00%.

Official website: www.mercantilebank.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1259.60 +4.21% JNJ Johnson & Johnson $254.30 +0.15% ABBV AbbVie Inc. $286.46 +1.67% UNH UnitedHealth Group Incorporated Common Stock (DE) $410.47 +3.75% MRK Merck & Company, Inc. Common Stock (new) $148.05 +0.46% NVS Novartis AG $151.35 +3.04% TMO Thermo Fisher Scientific Inc $692.33 +2.84% AZN AstraZeneca PLC $162.03 +3.99% AMGN Amgen Inc. $440.37 +3.35% GILD Gilead Sciences, Inc. $159.16 +3.66% ABT Abbott Laboratories $104.48 +2.09% NVO Novo Nordisk A/S $39.52 +3.66%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.